Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer.

Breast cancer research and treatment - 16 Sept 2026

Sanjari Moghaddam Ali, Deng Zhirui, Sereika Susan M, Habib Maryam, Homeniuk Anna, Brufsky Adam M, Rosenzweig Margaret Q

Abstract excerpt

PURPOSE: HER2-low breast cancer is treatment-relevant, but whether it is clinically distinct from HER2-0 disease remains unclear. We evaluate metastasis-free interval (MFI), first metastatic site, and survival after metastasis among HER2 classes in metastatic breast cancer. METHODS: We retrospectively examined patients with metastatic breast cancer classified as HER2-0, HER2-low, or HER2-positive. Analyses...

Read the complete abstract on PubMed

Topics

Humans
Female
Erb-b2 Receptor Tyrosine Kinases
Breast Neoplasms
Neoplasm Metastasis
Middle Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Phenotype

Retrospective Studies

Aged

Adult

Prognosis

Kaplan-Meier Estimate

Neoplasm Recurrence, Local

Biomarkers, Tumor

Source

Identifiers

PMID: 42747633
DOI: 10.1007/s10549-026-08067-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer.PMID 42747633Read ↗

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other BiomarkersSemantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?Semantic proximity Read ↗

Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.Semantic proximity Read ↗

Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site.Semantic proximity Read ↗

Discordance of HER2-low between primary tumors and matched distant metastases in breast cancerSemantic proximity Read ↗

Gene expression profiles of breast cancer metastasis according to organ siteSemantic proximity Read ↗

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.Semantic proximity Read ↗

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.Semantic proximity Read ↗

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.Semantic proximity Read ↗

BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.Semantic proximity Read ↗

Primary breast cancer phenotypes associated with propensity for central nervous system metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.